FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022307219> ?p ?o ?g. }

• W2022307219 endingPage "13" @default.
• W2022307219 startingPage "4" @default.
• W2022307219 abstract "The authors discuss the results of 3 studies of their group reflecting the possible role of amifostine in simultaneous radiochemotherapy (RCT) of advanced head and neck cancer. In a controlled phase II trial (1995 through 1996), 39 patients were included in this pilot investigation. A control group (n = 14) received simultaneous RCT of the head and neck region with an irradiation dose of 60 Gy and 2 cycles of carboplatin (700 mg/m(2) cumulative dose). Twenty-five patients received the same basic therapy and an additional 500-mg dose of amifostine before each chemotherapy. Amifostine was administered less than 45 minutes before the end of radiotherapy. The authors observed a dramatic reduction of typical radiotherapy-associated toxicities (mucositis, xerostomia, loss of taste, dysphagia). The hematologic side effects (leukocytopenia, anemia, thrombocytopenia) also were decreased significantly. The overall survival rate and locoregional control of both groups were comparable after 12 months. In a controlled intensification trial (1997 through 1999), the authors included 76 consecutive patients (69 men, 7 women) with pharyngeal cancer (oropharynx, n = 33; hypopharynx, n = 43). The tumors were characterized as unresectable and locally advanced without distant metastasis. All patients received a conventional radiotherapy (2-Gy single dose, daily fractionation) up to doses of 60 Gy and an additional 10 Gy as a boost in the tumor-infiltrated region. A dose of carboplatin, 70 mg/m(2), was given to a group of 45 patients on days 1 through 5 and 29 through 33 of radiotherapy (RCT arm). The resulting cumulative dose was 700 mg/m(2). A group of 31 patients (RCTintens arm) received the same dose of carboplatin on days 1 through 5, 22 through 26, and 43 through 47 or 1 through 5, 15 through 19, 29 through 33, and 43 through 47 of radiotherapy (cumulative dose 1.05 to 1.40 mg/m(2)). All patients received 500 mg of amifostine before each carboplatin administration. If the tumor volume was less than 20 cm(3), we observed an increased 1-year overall survival rate (91% v 71%) and time to progression (17 months v 10 months). If the tumor volume was greater than 20 cm(3), we observed comparable treatment results in both groups (1-year survival rate, 60% v 61%; time to progression, 13 months v 12 months). In a long-term follow-up investigation (1999 through 2000), 531 patients (89 women, 442 men) were analyzed according to their toxicities during regular follow-up investigations at our outpatient facility. All patients were treated by surgery or radio(chemo)therapy because of an advanced head and neck cancer. A total of 218 of 531 patients received the antineoplastic therapy without cytoprotection. An additional 313 patients received their RCT combined with amifostine administration before administration of the radiosensitizer. A significant influence of cytoprotection was registered in the following toxicities: xerostomia, fibrosis, loss of taste, and dysphagia. No impact was seen on the development of interstitial lymph edema and esophageal stenosis. Amifostine could be integrated in simultaneous radiochemotherapy of advanced head and neck cancer patients. The authors favor the administration of amifostine before chemotherapeutics alone. Selective cytoprotection could decrease the main acute toxicities (mucositis, xerostomia, dysphagia) as well as late side effects (xerostomia, loss of taste, fibrosis) of this form of combined treatment. The enhanced therapeutic index may be changed into a prognostic benefit for selected patients with unresectable tumors, if the volume is smaller than 20 cm(3)." @default.
• W2022307219 created "2016-06-24" @default.
• W2022307219 creator A5019533777 @default.
• W2022307219 creator A5042586777 @default.
• W2022307219 creator A5056359110 @default.
• W2022307219 creator A5068344570 @default.
• W2022307219 creator A5072495268 @default.
• W2022307219 date "2002-01-01" @default.
• W2022307219 modified "2023-10-17" @default.
• W2022307219 title "Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer" @default.
• W2022307219 cites W147424675 @default.
• W2022307219 cites W1936206127 @default.
• W2022307219 cites W1980609549 @default.
• W2022307219 cites W2034689526 @default.
• W2022307219 cites W2038294539 @default.
• W2022307219 cites W2095602776 @default.
• W2022307219 cites W2104854477 @default.
• W2022307219 cites W2106257072 @default.
• W2022307219 cites W2110337066 @default.
• W2022307219 cites W2147384904 @default.
• W2022307219 cites W2157885764 @default.
• W2022307219 cites W2263001911 @default.
• W2022307219 cites W2312400193 @default.
• W2022307219 cites W2421412785 @default.
• W2022307219 cites W2026471903 @default.
• W2022307219 doi "https://doi.org/10.1053/srao.2002.31356" @default.
• W2022307219 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11917277" @default.
• W2022307219 hasPublicationYear "2002" @default.
• W2022307219 type Work @default.
• W2022307219 sameAs 2022307219 @default.
• W2022307219 citedByCount "66" @default.
• W2022307219 countsByYear W20223072192012 @default.
• W2022307219 countsByYear W20223072192013 @default.
• W2022307219 countsByYear W20223072192014 @default.
• W2022307219 countsByYear W20223072192016 @default.
• W2022307219 countsByYear W20223072192017 @default.
• W2022307219 countsByYear W20223072192019 @default.
• W2022307219 countsByYear W20223072192021 @default.
• W2022307219 countsByYear W20223072192023 @default.
• W2022307219 crossrefType "journal-article" @default.
• W2022307219 hasAuthorship W2022307219A5019533777 @default.
• W2022307219 hasAuthorship W2022307219A5042586777 @default.
• W2022307219 hasAuthorship W2022307219A5056359110 @default.
• W2022307219 hasAuthorship W2022307219A5068344570 @default.
• W2022307219 hasAuthorship W2022307219A5072495268 @default.
• W2022307219 hasConcept C126322002 @default.
• W2022307219 hasConcept C126894567 @default.
• W2022307219 hasConcept C141071460 @default.
• W2022307219 hasConcept C168563851 @default.
• W2022307219 hasConcept C2776530083 @default.
• W2022307219 hasConcept C2776694085 @default.
• W2022307219 hasConcept C2778239845 @default.
• W2022307219 hasConcept C2778496288 @default.
• W2022307219 hasConcept C2779387952 @default.
• W2022307219 hasConcept C2781451048 @default.
• W2022307219 hasConcept C2909463153 @default.
• W2022307219 hasConcept C509974204 @default.
• W2022307219 hasConcept C71924100 @default.
• W2022307219 hasConceptScore W2022307219C126322002 @default.
• W2022307219 hasConceptScore W2022307219C126894567 @default.
• W2022307219 hasConceptScore W2022307219C141071460 @default.
• W2022307219 hasConceptScore W2022307219C168563851 @default.
• W2022307219 hasConceptScore W2022307219C2776530083 @default.
• W2022307219 hasConceptScore W2022307219C2776694085 @default.
• W2022307219 hasConceptScore W2022307219C2778239845 @default.
• W2022307219 hasConceptScore W2022307219C2778496288 @default.
• W2022307219 hasConceptScore W2022307219C2779387952 @default.
• W2022307219 hasConceptScore W2022307219C2781451048 @default.
• W2022307219 hasConceptScore W2022307219C2909463153 @default.
• W2022307219 hasConceptScore W2022307219C509974204 @default.
• W2022307219 hasConceptScore W2022307219C71924100 @default.
• W2022307219 hasIssue "1" @default.
• W2022307219 hasLocation W20223072191 @default.
• W2022307219 hasLocation W20223072192 @default.
• W2022307219 hasOpenAccess W2022307219 @default.
• W2022307219 hasPrimaryLocation W20223072191 @default.
• W2022307219 hasRelatedWork W2002493963 @default.
• W2022307219 hasRelatedWork W2064900812 @default.
• W2022307219 hasRelatedWork W2394908553 @default.
• W2022307219 hasRelatedWork W2405171317 @default.
• W2022307219 hasRelatedWork W2412009112 @default.
• W2022307219 hasRelatedWork W2740182855 @default.
• W2022307219 hasRelatedWork W3029959225 @default.
• W2022307219 hasRelatedWork W3150124368 @default.
• W2022307219 hasRelatedWork W4231799438 @default.
• W2022307219 hasRelatedWork W335556741 @default.
• W2022307219 hasVolume "12" @default.
• W2022307219 isParatext "false" @default.
• W2022307219 isRetracted "false" @default.
• W2022307219 magId "2022307219" @default.
• W2022307219 workType "article" @default.